Immune Repertoire of Ovarian HGSC

Immune Repertoire Clinical Trial

Official title:

Differential Expression of Immune Repertoire of T/B Lymphocytes in Ovarian High Grade Serous Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03794115
• Other study ID #: EOC-IMMUNE
• Status: Recruiting
• Start date: January 3, 2019
• Est. completion date: January 1, 2022

Study information

• Verified date: January 2019
• Source: Peking Union Medical College Hospital
• Contact: Lei Li, M.D.
• Phone: +8613911988831
• Email: lileigh[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this preliminary study, peripheral blood and carcinoma tissue with pericarcinomatous tissue are taken from the patients with ovarian high grade serous carcinoma at several points: before any treatment, after the debulking surgery, and after all the proposed chemotherapy. The differential expression of the T/B lymphocyte receptors in these samples will be analyzed with the platinum-based treatment and survival outcomes of the patients. The primary objective is the expression rates of T/B lymphocyte receptors in different stages of checking points.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: January 1, 2022
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Confirmed of primary ovarian high grade serous carcinoma

• Aged 18 years or older

• No immunosuppressive disease

• Signed an approved informed consents

Exclusion Criteria:

• Not meeting all of the inclusion criteria

Related Conditions & MeSH terms

• B Lymphocyte Receptor
• Carcinoma
• Immune Repertoire
• Ovarian High Grade Serous Carcinoma
• T Lymphocyte Receptor

Intervention

Procedure:
• Treatment for ovarian cancer
The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.

Locations

Country	Name	City	State
China	Lei Li	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Lei Li

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expression rates of T lymphocyte receptors	Expression rates of T lymphocyte receptors in different stages of checking points, including timings before any treatment, after the debulking surgery, and after all the proposed chemotherapy	One year
Primary	Expression rates of B lymphocyte receptors	Expression rates of T lymphocyte receptors in different stages of checking points, including timings before any treatment, after the debulking surgery, and after all the proposed chemotherapy	One year